Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$27.3 million.

  • Kymera Therapeutics' Free Cash Flow rose 4541.91% to -$27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.2 million, marking a year-over-year decrease of 5533.64%. This contributed to the annual value of -$207.3 million for FY2024, which is 5100.51% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Free Cash Flow of -$27.3 million as of Q3 2025, which was up 4541.91% from -$60.6 million recorded in Q2 2025.
  • Kymera Therapeutics' Free Cash Flow's 5-year high stood at -$3.6 million during Q4 2023, with a 5-year trough of -$79.6 million in Q1 2025.
  • Its 5-year average for Free Cash Flow is -$42.0 million, with a median of -$39.9 million in 2022.
  • As far as peak fluctuations go, Kymera Therapeutics' Free Cash Flow soared by 9102.96% in 2023, and later crashed by 165195.53% in 2024.
  • Kymera Therapeutics' Free Cash Flow (Quarter) stood at -$38.9 million in 2021, then decreased by 2.72% to -$39.9 million in 2022, then surged by 91.03% to -$3.6 million in 2023, then crashed by 1651.96% to -$62.7 million in 2024, then soared by 56.49% to -$27.3 million in 2025.
  • Its Free Cash Flow was -$27.3 million in Q3 2025, compared to -$60.6 million in Q2 2025 and -$79.6 million in Q1 2025.